Amsterdam, The Netherlands, (AP) The study found that doctors believe can contribute to rapid stabilization of a heart attack, reduce the mortality or morbidity as a anticoagulant disappointing. Drugs such as abciximab in patients with heart arteries interventional treatment, such as angioplasty to prevent clotting of blood cell adhesion to save lives, so that these operations even more safe and effective. Impressed with its effects, so researchers hope it can improve the prognosis of patients with non-surgical treatment. However, the study found that it does not have the slightest effect.
The European Heart Association meeting held on Monday announced the discovery. In a study of 7800 cases of severe chest pain caused by heart attack patients in an international study, all patients had mild anticoagulant quickly taking the role of aspirin and heparin, as a basis for therapeutic measures. These patients a high risk of heart attack because they did not completely block the blood flow in artery embolization.
In addition to aspirin and blood thinners, the half of the patients in 24 or 48 hours of intravenous abciximab, the other half entered a placebo. The study examined the first month to whether abciximab can reduce heart attack or death in patients with the opportunity. Did not use abciximab in patients treated with 8% of disease or death, the importation of the drug 24 hours and 48 hours of patients were 8.2% and 9.6% incidence.
The study’s principal member of the Erasmus University Hospital Rotterdam, the Netherlands (Erasmus University Hospital), Dr Maarten Simoons professor of medicine, said, “it does not show any benefit to patients.” At the same time, each group has about 2% of The patients need to lift artery embolization. Some researchers hope the drug will enable patients to avoid surgery or angioplasty. Simoons said, “some of us who think this is feasible. All of the data support that.”
Simoons, said the study found no effect of abciximab may be good because of its use has not yet to produce significant differences in the extent or timing of application of the drug too late. Abciximab in general in the preoperative and intraoperative application of 12 hours. New York, Mount Sinai School of Medicine (Mount Sinai School of Medicine), Professor Dr. Michael Farkouh, said the drug can still be carried out within a few hours artery surgery did not contribute to heart disease. But he added that, to some extent, the results of this study was not a surprise. “We have always maintained that these drugs are for interventional therapy in patients with the best choice,” he said, “That is all the evidence.”
